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Abstract. Numerous studies in animal models estab-
lished a key role of the C-jun N-terminal kinase (JNK) 
family (JNK1, JNK2 and JNK3) in numerous pathologi-
cal conditions, including cancer, cardiac hypertrophy and 
failure, neurodegenerative disorders, diabetes, arthritis 
and asthma. A possible function of JNK in atheroscle-
rosis remained uncertain since conclusions have mainly 
been based on in vitro studies investigating endothelial 
cell activation, T-effector cell differentiation and prolif-
eration of vascular smooth muscle cells, all of which rep-
resent crucial cellular processes involved in atheroscle-
rosis. However, recent experiments demonstrated that 
macrophage-restricted deletion of JNK2 was suffi cient to 
effi ciently reduce atherosclerosis in mice. Furthermore, it 
has been shown that JNK2 specifi cally promotes scaven-
ger receptor A-mediated foam cell formation, an essen-
tial step during early atherogenesis, which occurs when 
vascular macrophages internalize modifi ed lipoproteins. 
Thus, specifi c inhibition of JNK2 activity may emerge as 
a novel and promising therapeutic approach to attenuate 
atheroma formation in the future. In this review, we dis-
cuss JNK-dependent cellular and molecular mechanisms 
underlying atherosclerosis.
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Introduction
So far, three distinct MAPK pathways have been de-
scribed in mammalian cells: the extracellular signal-
regulated kinase (ERK) pathway, the c-Jun-N-terminal 
kinase (JNK) pathway and the p38 MAPK pathway. In 
general, the ERKs are activated by mitogenic stimuli, 
whereas the JNKs and p38 MAPKs respond to environ-
mental stress, including ultraviolet light, heat, osmotic 
shock and infl ammatory cytokines [1, 2].
The JNK protein kinases are encoded by three genes: 
JNK1, JNK2 and JNK3. JNK1 and JNK2 are expressed 
ubiquitously. In contrast, expression of JNK3 is largely 
restricted to brain, heart and testis. Transcripts derived 
from these genes are alternatively spliced to create four 
JNK1 isoforms, four JNK2 isoforms and two JNK3 
isoforms [3]. Extracellular stimuli, including stress and 
cytokines, lead to the activation of mitogen-activated 
protein kinase kinase kinases (MAPKKKs) that in turn 
activate MAP kinase kinase 4 or 7 (MKK4 and MKK7), 
both of which phosphorylate the tyrosine and threonine 
residues within the dual phosphorylation motif Thr-Pro-
Tyr located in the activation loop of JNK [2, 4]. JNK 
activation results in phosphorylation of a number of tran-
scription factors, including the c-Jun component of the 
activator protein-1 (AP-1) transcription family, but also 
other cellular proteins. JNK inactivation is regulated by 
serine and tyrosine phosphatases, and by a family of dual 
specifi city MAPK phosphatases [4]. Loss-of-function 
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studies in mice provided major insights into the function 
of JNK genes in development and disease. JNK1, JNK2 
as well as JNK3 null mice appeared morphologically 
normal, but simultaneous disruption of JNK1 and JNK2 
resulted in embryonic lethality [5, 6]. More detailed 
analysis revealed that JNK1 and JNK2 knockout mice 
are immunocompromised due to defects in effector T cell 
differentiation and cytokine production [7]. Further stud-
ies using animal disease models defi ned specifi c roles of 
JNK genes in a remarkable variety of pathologic condi-
tions, such as cancer development [8], cardiac hypertro-
phy and heart failure [9], neurodegenerative disorders 
such as Parkinson’s disease [10, 11] and Alzheimer’s dis-
ease [12], obesity-associated type II diabetes [13], type 
I diabetes [14], arthritis [15, 16] and asthma [17–19]. In 
this review, we summarize recent fi ndings about JNK and 
its function in atherogenesis [20].
JNK2 but not JNK1 represents a key player in 
 atherogenesis
In broad terms, atherosclerosis represents a systemic 
infl ammatory and metabolic disease triggered by a com-
plex interplay of numerous cell types, including T cells, 
macrophages, hepatocytes, enterocytes and vascular cells 
[21]. Recent studies indicated that JNK becomes highly 
activated in atherosclerotic lesions in humans [22] and 
rabbits [23]. Activated JNK was shown to localize mainly 
in vascular smooth muscle cells and macrophages. In the 
study conducted by Ricci et al., a very prominent phos-
phorylation and thus activation of JNK in total protein 
extracts from murine atherosclerotic lesions compared 
with normal vessels was observed [20]. The 10 known 
splicing variants of the three JNK genes give rise to 
proteins that have either a molecular weight of 46 kDa 
(smaller isoforms) or 55 kDa (bigger isoforms). Interest-
ingly, only the bigger isoforms were phosphorylated, 
while similar levels of total JNK was detected at both 
molecular weights in diseased and control vessels.
Ricci et al. then investigated the in vivo function of JNK1 
and JNK2 in atherogenesis using the ApoE–/– mice as a 
model for atherosclerosis and could demonstrate geneti-
cally that JNK2 but not JNK1 represents a key player in 
atherosclerosis in mice. Furthermore, pharmacological 
inhibition of JNK activity for a relatively short time 
period (4 weeks) using the small molecule inhibitor 
SP600125 effi ciently inhibited atherosclerosis.
A more detailed pharmacological study will be neces-
sary to consider JNK inhibition as a possible treatment 
modality in patients. An important question is whether 
treatment with a JNK inhibitor leads to inhibition or even 
regression of atherosclerotic lesions. For that purpose, 
different time points and treatment periods need to be 
included in the study. Given the broad activity of JNK 
in many cellular processes, treatment with global JNK 
inhibitors might lead to severe side effects in patients. 
Therefore, studies with JNK2-selective inhibitors should 
be considered. At present, most scientists focus on de-
velopment and testing of JNK1-specifi c inhibitors. How-
ever, the study by Ricci et al. [20] and other recent studies 
[14, 16] clearly provide evidence for the requirement of 
inhibitors against JNK2 in specifi c disease settings. How-
ever, one should keep in mind that existing mouse models 
for atherosclerosis do not fully refl ect the situation of hu-
man atherosclerosis and that inhibition of JNK2 alone, 
although probably associated with fewer side effects 
when compared with broader spectrum inhibitors, will 
not be suffi cient to effi ciently attenuate atherosclerosis 
in humans.
In the remaining part of this review we analyze the pos-
sible cellular and molecular mechanisms by which JNK 
exerts its pro-atherogenic functions.
The role of JNK in endothelial cell activation 
Vascular endothelial cell activation upon pro-infl am-
matory stimuli such as tumor necrosis factor a (TNFa) 
and interlekin (IL)-1 is manifested through expression 
of adhesion molecules such as vascular cell adhesion 
molecule-1 (VCAM-1), intercellular adhesion molecule-
1 (ICAM-1) and selectins (P-, E- and L-selectins) [24]. 
Genetic experiments in vivo revealed importance for 
these molecules in the early pathogenesis of atheroscle-
rosis [25–28].
Previous work mainly established an important role for 
JNK in TNFa-triggered apoptosis [29–31]. However, 
several laboratories also reported a possible role for JNK 
in TNFa-mediated endothelial cell activation. In two 
studies, it has been demonstrated that the JNK signal-
ing pathway is specifi cally required for the induction 
of E-selectin expression induced by TNFa [32, 33]. 
Moreover, AP-1 transcription factors, in particular the 
JNK target c-jun, mediate the effect of TNFa-induced 
VCAM-1 expression in endothelial cells through inter-
action with NF-kappaB [34]. Another research group 
reported that activation of the JNK pathway leads to 
ICAM-1 expression [35]. To our knowledge, none of 
the experiments addressing endothelial cell activation 
have been conducted in primary JNK1 or JNK2 knock-
out endothelial cells. Nevertheless, several experiments 
suggest that TNFa-mediated cellular processes seem to 
be controlled mainly by JNK1 and not JNK2 [29, 31, 
33]. Consistently, deletion of JNK2 did not result in 
altered E-selectin, VCAM-1 and ICAM-1 expression in 
atherosclerotic vessels. As mentioned above, inactivation 
of JNK1 did not signifi cantly inhibit atherosclerosis in 
ApoE-defi cient mice. Hence, although a possible role for 
JNK1 in endothelial cell activation has not been excluded 
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in the study by Ricci et al. [20], it is reasonable to assume 
that this process will not be of major relevance in the 
context of atherosclerosis.
Impact of JNK on vascular smooth muscle cell 
 proliferation and migration
Transition of early plaques to more complex lesions is 
characterized by migration and proliferation of vascular 
smooth muscle cells (VSMCs) into the intima [21].
Importantly, the AP-1 member c-jun seems to be required 
for both platelet-derived growth factor (PDGF)-induced 
VSMC migration and proliferation [36, 37]. Further-
more, inhibition of JNK activity using recombinant 
adenovirus containing a dominant-negative mutant of 
JNK attenuates PDGF-induced VSMC migration and 
proliferation in vitro [38]. Although studies in mouse 
embryonic fi broblasts showed specifi c roles for JNK1 
and JNK2 in proliferation [39], the study by Ricci et al. 
demonstrated that inactivation of JNK1 and JNK2 did not 
lead to a signifi cant change in proliferation of VSMCs in 
vitro in response to PDGF. It has also been demonstrated 
that migration was not affected in the absence of JNK2. 
However, it should be noted here that other potential 
mitogenic factors, such as thrombin, have been shown to 
activate JNK in VSMCs [40]. But immunohistochemistry 
using a VSMC-specifi c marker did not reveal increased 
amounts of VSMCs in plaques of ApoE–/– compared with 
ApoE–/– JNK2–/– mice [20]. Thus, inactivation of JNK2 
seems not to be suffi cient to attenuate VSMC prolifera-
tion and migration, at least not in the context of athero-
sclerosis.
JNK is a key player in T effector cell differentiation
The role of adaptive immunity in development of athero-
sclerosis has been broadly investigated [41]. Within the 
atheroma, CD4-positive T-helper cells can polarize into 
those secreting generally pro-infl ammatory cytokines 
(known as Th1 cells) and those secreting predominantly 
anti-infl ammatory cytokines (denoted as Th2 cells). In 
general, Th1 cells predominate in the atheroma. They 
secrete interferon-g (IFNg), IL-2, and TNF-a and -b, 
which cause macrophage activation, vascular activation 
and infl ammation. Th2 cytokines such as IL-4, IL-5 and 
IL-10 are less abundant than cytokines of the Th1 type in 
end-stage human atherosclerotic lesion [42].
The JNK signaling pathway has been implicated in the 
immune response that is mediated through differentiation 
of CD4+ helper T (Th) cells into Th1 and Th2 effector 
cells. JNK1-defi cient T cells hyperproliferated, exhib-
ited decreased activation-induced cell death, and pref-
erentially differentiated to Th2 cells, which in turn led 
to enhanced production of Th2 cytokines such as IL-4, 
IL5 and IL-10. Likewise, the differentiation of precursor 
CD4+ T cells into Th1 but not Th2 effector cells is im-
paired in JNK2-defi cient mice. The inability of IL-12 to 
differentiate JNK2-defi cient CD4+ T cells fully into Th1 
effector cells is caused by a defect in IFNg production 
during the early stages of differentiation [7, 43–46].
Although clear evidence for a role of T cells has been 
obtained in mouse models of atherogenesis [47-49], 
complete lymphocyte defi ciency did not alter develop-
ment of atherosclerosis in ApoE-defi cient mice in which 
acceleration of atherogenesis was induced by feeding 
mice with a high-cholesterol diet [50, 51]. Therefore, the 
atherosclerosis model which was used by Ricci et al. very 
likely was T cell-independent. This is also supported by 
the fact that there was no effect on atherosclerosis in the 
absence of JNK1, although very similar T cell defects 
have been reported for both JNK1 and JNK2, and identi-
cal genetic backgrounds have been used. However, these 
fi ndings do not exclude a possible JNK-dependent effect 
on lymphocyte differentiation in more chronic and im-
munogenic murine and human atherosclerotic lesions.
Impaired lipid processing in JNK2–/– macrophages
In normal circumstances, the endothelial monolayer 
resists fi rm adhesion of monocytes upon contact with 
fl owing blood. However, upon exposure with pro-infl am-
matory factors, endothelial cells increase the expression 
of various leukocyte adhesion molecules, which enable 
monocytes to adhere to the endothelial cell membrane 
[52]. Adhesion is followed by transmigration of mono-
cytes through the endothelial layer into the intima. This 
is governed by chemotactic factors produced in the sub-
endothelial layer. Migrated monocytes become tissue-
resident macrophages which in turn develop into lipid-
loaded foam cells upon exposure to modifi ed lipoproteins 
[53]. In foam cells, the membranes become enriched in 
unesterifi ed cholesterol and cytoplasmic cholesteryl ester 
droplets as well as lysosomal cholesterol crystals form. 
On the other hand, the macrophages are able to remove 
at least partially excessive cellular cholesterol. The 
cholesterol effl ux process is mediated by high-density 
lipoproteins (HDLs) and especially particles containing 
only apolipoprotein A-I (apoA-I). Reverse cholesterol 
transport from macrophages to the liver is regarded as a 
central anti-atherogenic process. Recently it has become 
clear that cholesterol effl ux is a highly regulated process 
that is mediated by specifi c molecules, including ATP-
binding cassette (ABC) transporters [54]. At the same 
time, macrophages are important regulators of the innate 
immune system, and infl ammatory pathways induced in 
activated macrophages are pivotal for the pathogenesis of 
atherosclerois [55].
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As described above, the study by Ricci et al. could 
largely exclude a function of JNK2 in endothelial cells 
and vascular smooth muscle cells in the context of 
atherosclerosis. Importantly, inactivation of JNK2 also 
did not alter the plasma lipid profi le in ApoE-defi cient 
mice. However, this study presented clear evidence 
that JNK2 but not JNK1 is required for effi cient foam 
cell formation in vitro. Defective foam cell formation 
in JNK2-defi cient macrophages was caused by defec-
tive uptake and degradation of modifi ed lipoproteins 
(acetylated LDL). Interestingly, JNK2-defi cient mac-
rophages also showed a two-fold increase in binding 
of acetylated LDL (acLDL) (see below). Intriguingly, 
cellular apoprotein AI (ApoAI)-mediated cholesterol 
effl ux was markedly increased in the absence of JNK2, 
which might also contribute to defective foam cell forma-
tion in JNK2-defi cient macrophages. Yet the molecular 
mechanism by which JNK2 attenuates cholesterol effl ux 
in macrophages is currently unknown. Most important, it 
has also been shown that macrophage-restricted deletion 
of JNK2 was suffi cient to reduce atherosclerosis in mice 
using bone marrow transplantation experiments [20]. In 
fact, the bone marrow transplantation experiments further 
exclude any effect of the absence of JNK2 on endothe-
lial cells and VSMCs. However, it is not clear whether 
JNK2 is also involved in activation of macrophages and 
controls secretion of infl ammatory cytokines in this cell 
type, which might also contribute to the development of 
atherosclerosis. A recent intriguing study suggests that 
MAPKs, including JNKs, convert cholesterol loading 
of cells into expression of pro-infl ammatory cytokines 
at the RNA and protein level [56]. Therefore, more work 
addressing the role of JNK2 in macrophage-dependent 
infl ammation is required.
Overall, these data provide evidence that JNK2-depend-
ent foam cell formation could represent a crucial event in 
atherosclerosis.
JNK2 controls the abundance and phosphorylation of 
scavenger receptor A
Transition of macrophages into foam cells is triggered by 
extensive uptake of modifi ed lipoproteins [57]. Uptake 
of modifi ed lipoproteins has been shown to be mediated 
mainly by scavenger receptor A (SR-A) and CD36 since 
uptake of modifi ed low-density lipoproteins (LDLs) is 
reduced by almost 90% in macrophages lacking SR-A 
and CD36 simultaneously [58]. Importantly, SR-A alone 
mediates approximately 30–50% of uptake of modifi ed 
lipoproteins [58]. However, the role of SR-A in athero-
genesis remains controversial. The most striking evidence 
that demonstrates a pro-atherogenic role for this receptor 
resulted from the initial study by Suzuki et al. [59] in 
which atherosclerosis-prone ApoE–/– mice were crossed 
with SR-A–/– mice. These double mutant mice showed re-
duced atherosclerosis compared to ApoE–/– SR-A+/+ mice. 
Since this initial report, a number of confl icting data on 
the role of SR-A in atherogenesis have been published. 
In a study by de Winther et al. [60], mice expressing 
Apolipoprotein E3Leiden, a dysfunctional ApoE vari-
ant associated with familial dysbetalipoproteinemia in 
humans, were crossed with SR-A–/– mice. Surprisingly, 
these mice showed slightly increased lesion formation in 
the absence of SR-A. Consistent with the study of Suzuki 
et al. [59], another study showed that mice defi cient for 
total or macrophage-specifi c expression of SR-A exhib-
ited decreased atherosclerosis [61]. Gain-of-function 
experiments in mice also led to inconsistent results. One 
study demonstrated no effect on atherosclerosis when 
human SR-A was ectopically expressed in macrophages 
in LDL receptor-defi cient mice [62]. Another study even 
demonstrated decreased atherosclerosis upon macro-
phage-specifi c overexpression of bovine SR-A in LDL 
receptor-defi cient mice [63]. Overall, the experiments 
Figure 1. The role of JNK2 in lipid homeostasis and infl ammation 
in macrophages. JNK2 promotes uptake of modifi ed lipoproteins 
(mLDLs) and suppresses cholesterol (Chol.) effl ux in macrophages. 
Extensive uptake of modifi ed lipoproteins triggers foam cell forma-
tion, while reverse cholesterol transport from macrophages attenu-
ates this process. Foam cell formation is a crucial step in promoting 
early atherogenesis. JNK2 might also promote infl ammation and 
plaque formation by regulating secreation of pro-infl amatory cy-
tokines in macrophages loaded with cholesterol.
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in mice have been conducted in different genetic back-
grounds and different mouse models of atherosclerosis. 
Moreover, the expression of human or bovine SR-A in 
mice might lead to completely misleading results since 
even small amino acid sequence differences might give 
rise to completely aberrant functions in foreign species. 
Therefore, these experiments should be interpreted very 
carefully.
The study by Ricci et al. has demonstrated that protein 
abundance of SR-A is increased in macrophages lacking 
JNK2 compared with wild-type cells, which has been 
confi rmed by immunofl uorescence, Western blotting 
and immunohistochemistry, while RNA levels were 
unchanged. In addition, JNK2-defi cient macrophages 
displayed fi lopodia-like projections, which has been 
associated with increased SR-A expression [64]. Since 
SR-A is responsible for binding and uptake mainly 
of the acetylated form of LDL (acLDL), these results 
would imply that binding and uptake of acLDL would 
be increased in JNK2-defi cient cells. Indeed, increased 
binding of acLDL could be observed. However, it was 
clearly demonstrated by two independent series of 
experiments that uptake and degradation of acLDL 
was severely decreased in the absence of JNK2. Thus, 
although the receptor seems to be more abundantly ex-
pressed and can bind more acLDL, it cannot be internal-
ized effi ciently. Three studies indicated that phospho-
rylation of specifi c serines located in the cytoplasmic 
tail of SR-A were required for effi cient SR-A-mediated 
uptake of modifi ed LDLs [65–67]. Indeed, experiments 
revealed that SR-A phosphorylation was markedly 
reduced in macrophages lacking JNK2. Thus, JNK2 
promotes phosphorylation of SR-A and is required for 
effi cient SR-A-mediated lipid internalization in macro-
phages. Moreover, decreased phosphorylation of SR-A 
could lead to increased stability of this receptor and 
thus could explain the increased abundance of SR-A. 
However, the exact mechanisms affecting stability of 
SR-A in the absence of JNK2 need to be further inves-
tigated. It also needs to be determined whether JNK2 
is phosphorylating SR-A directly, or whether it induces 
downstream pathways which in turn lead to phosphor-
ylation of SR-A.
Involvement of JNK in the advanced stage of 
 atherosclerosis
In the advanced stage of plaque formation, atheroscle-
rotic lesions can rupture at least partially due to degrada-
tion of the extracellular matrix by various proteases such 
as collagenases and matrix metaloproteinases (MMPs), 
exposing tissue factors to blood components, which leads 
to coagulation and thrombosis [21, 68]. 
Various studies reported that MMP9, which is highly 
expressed in atherosclerotic plaques, is regulated by JNK 
[69–72]. The expression of MMP1 was found to be at 
least partly mediated by JNK [73], and likewise MMP13 
was shown to be controlled by JNK in a murine arthritis 
model [15]. These studies indicate that JNK might be 
involved in the process of plaque rupture. 
Platelets play a key role in hemostasis and thrombosis. 
The formation of a platelet plug is accompanied by the 
generation of thrombin, which results in the generation 
of fi brin required for stabilization of the platelet plug. 
Thrombin is a potent platelet activator, which proceeds 
through proteolysis of the protease activated receptors 
(PARs) [74]. Indeed, thrombin as well as von Willebrand 
factor, another potential activator of platelets, have been 
shown to activate JNK in human platelets [75, 76]. How-
ever, the lack of a well-established mouse model for 
plaque rupture and thrombosis complicates experimental 
design, and therefore a possible role for JNK in late-stage 
atherosclerosis remains highly speculative [77].
Conclusions
JNK has been shown to be implicated in most of the 
cellular processes involved in the development of athero-
sclerosis. The recent in vivo study by Ricci et al. revealed 
that JNK2 controls lipid homeostasis in macrophages 
and thus represents a key player in atherosclerosis. These 
fi ndings rather imply that JNK-dependent effects ob-
served in endothelial cells, VSMCs and T cells probably 
Figure 2. JNK2 promotes SR-A-mediated lipid internalization in 
macrophages. Left panel: JNK2 indirectly or directly phospho-
rylates SR-A (receptor in blue), which allows internalization of 
receptor-bound lipoproteins (in red). Right panel: In the absence 
of JNK2, the receptor is less phosphorylated and is more abundant 
on the surface, allowing more binding of lipoproteins and increased 
adherence of macrophages. However, internalization is no longer 
effi cient.
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play a minor role in the context of atherosclerosis even 
though compensatory functions of JNK1 and JNK2 could 
not be excluded in these cells. Overall, specifi c inhibition 
of JNK2 could be considered to prevent lesion develop-
ment in humans. 
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